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A B S T R A C T
Background
Pelvic organ prolapse is a common problem in women. About 40% of women will experience prolapse in their lifetime, with the
proportion expected to rise in line with an ageing population. Women experience a variety of troublesome symptoms as a consequence
of prolapse, including a feeling of 'something coming down' into the vagina, pain, urinary symptoms, bowel symptoms and sexual
diIiculties. Treatment for prolapse includes surgery, pelvic floor muscle training (PFMT) and vaginal pessaries. Vaginal pessaries are
passive mechanical devices designed to support the vagina and hold the prolapsed organs back in the anatomically correct position. The
most commonly used pessaries are made from polyvinyl-chloride, polythene, silicone or latex. Pessaries are frequently used by clinicians
with high numbers of clinicians oIering a pessary as first-line treatment for prolapse.
This is an update of a Cochrane Review first published in 2003 and last published in 2013.
Objectives
To assess the eIects of pessaries (mechanical devices) for managing pelvic organ prolapse in women; and summarise the principal findings
of relevant economic evaluations of this intervention.
Search methods
We searched the Cochrane Incontinence Specialised Register which contains trials identified from the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP and
handsearching of journals and conference proceedings (searched 28 January 2020). We searched the reference lists of relevant articles and
contacted the authors of included studies.
Selection criteria
We included randomised and quasi-randomised controlled trials which included a pessary for pelvic organ prolapse in at least one arm
of the study.
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Data collection and analysis
Two review authors independently assessed abstracts, extracted data, assessed risk of bias and carried out GRADE assessments with
arbitration from a third review author if necessary.
Main results
We included four studies involving a total of 478 women with various stages of prolapse, all of which took place in high-income countries.
In one trial, only six of the 113 recruited women consented to random assignment to an intervention and no data are available for those
six women. We could not perform any meta-analysis because each of the trials addressed a diIerent comparison. None of the trials
reported data about perceived resolution of prolapse symptoms or about psychological outcome measures. All studies reported data about
perceived improvement of prolapse symptoms.
Generally, the trials were at high risk of performance bias, due to lack of blinding, and low risk of selection bias. We downgraded the
certainty of evidence for imprecision resulting from the low numbers of women participating in the trials.
Pessary versus no treatment: at 12 months' follow-up, we are uncertain about the eIect of pessaries compared with no treatment on
perceived improvement of prolapse symptoms (mean diIerence (MD) in questionnaire scores -0.03, 95% confidence interval (CI) -0.61 to
0.55; 27 women; 1 study; very low-certainty evidence), and cure or improvement of sexual problems (MD -0.29, 95% CI -1.67 to 1.09; 27
women; 1 study; very low-certainty evidence). In this comparison we did not find any evidence relating to prolapse-specific quality of life
or to the number of women experiencing adverse events (abnormal vaginal bleeding or de novo voiding diIiculty).
Pessary versus pelvic floor muscle training (PFMT): at 12 months' follow-up, we are uncertain if there is a diIerence between pessaries
and PFMT in terms of women's perceived improvement in prolapse symptoms (MD -9.60, 95% CI -22.53 to 3.33; 137 women; low-certainty
evidence), prolapse-specific quality of life (MD -3.30, 95% CI -8.70 to 15.30; 1 study; 116 women; low-certainty evidence), or cure or
improvement of sexual problems (MD -2.30, 95% -5.20 to 0.60; 1 study; 48 women; low-certainty evidence). Pessaries may result in a large
increase in risk of adverse events compared with PFMT (RR 75.25, 95% CI 4.70 to 1205.45; 1 study; 97 women; low-certainty evidence).
Adverse events included increased vaginal discharge, and/or increased urinary incontinence and/or erosion or irritation of the vaginal
walls.
Pessary plus PFMT versus PFMT alone: at 12 months' follow-up, pessary plus PFMT probably leads to more women perceiving
improvement in their prolapse symptoms compared with PFMT alone (RR 2.15, 95% CI 1.58 to 2.94; 1 study; 260 women; moderate-certainty
evidence). At 12 months' follow-up, pessary plus PFMT probably improves women's prolapse-specific quality of life compared with PFMT
alone (median (interquartile range (IQR)) POPIQ score: pessary plus PFMT 0.3 (0 to 22.2); 132 women; PFMT only 8.9 (0 to 64.9); 128 women;
P = 0.02; moderate-certainty evidence). Pessary plus PFMT may slightly increase the risk of abnormal vaginal bleeding compared with
PFMT alone (RR 2.18, 95% CI 0.69 to 6.91; 1 study; 260 women; low-certainty evidence). The evidence is uncertain if pessary plus PFMT
has any eIect on the risk of de novo voiding diIiculty compared with PFMT alone (RR 1.32, 95% CI 0.54 to 3.19; 1 study; 189 women; low-
certainty evidence).
Authors' conclusions
We are uncertain if pessaries improve pelvic organ prolapse symptoms for women compared with no treatment or PFMT but pessaries in
addition to PFMT probably improve women's pelvic organ prolapse symptoms and prolapse-specific quality of life. However, there may
be an increased risk of adverse events with pessaries compared to PFMT. Future trials should recruit adequate numbers of women and
measure clinically important outcomes such as prolapse specific quality of life and resolution of prolapse symptoms. 
The review found two relevant economic evaluations. Of these, one assessed the cost-eIectiveness of pessary treatment, expectant
management and surgical procedures, and the other compared pessary treatment to PFMT.
P L A I N   L A N G U A G E   S U M M A R Y
Pessaries (mechanical devices) for managing pelvic organ prolapse in women
Review question
How eIective are pessaries (mechanical devices) for managing pelvic organ prolapse in women?
Background
Pelvic organs, such as the uterus, bladder or bowel, may protrude into the vagina because of weakness in the tissues that normally support
them. This protrusion is known as pelvic organ prolapse. Women who experience prolapse report a wide variety of symptoms that aIect
their quality of life. The choice of treatment options for pelvic organ prolapse symptoms is dictated largely by patient choice, as the
interventions of lifestyle changes, pelvic floor muscle training (PFMT), pessary and surgery are very diIerent with diIerent complication
risks. Vaginal pessaries are one treatment option for prolapse that are commonly used to restore the prolapsed organs to their normal
position and hence relieve symptoms. A vaginal pessary can be used to treat all four prolapse stages.
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How up-to-date is this review?
We searched for studies published up to 28 January 2020.
Study characteristics
We found four studies involving 478 women with various stages of prolapse. All four studies were carried out in high-income countries.
Key results
None of the studies reported whether or not the women's prolapse symptoms were completely resolved. We are uncertain about the eIect
of pessaries compared with no treatment on perceived improvement of prolapse symptoms, and cure or improvement of sexual problems.
We did not find any evidence relating to the risk of vaginal bleeding or diIiculty urinating in the studies comparing pessaries with no
treatment.
We are uncertain if pessaries have any eIect on improving women's prolapse symptoms when pessary is compared with PFMT. The
evidence is also very uncertain about the eIect of pessaries compared with PFMT on prolapse-specific quality of life and on sexual
problems. Pessaries may result in a greater risk of adverse events, including vaginal discharge, increased urinary incontinence and erosion
of the vaginal walls, compared with PFMT.
Pessary plus PFMT probably leads to more women perceiving improvement in their prolapse symptoms and in their prolapse-specific
quality of life compared with PFMT alone. Compared with PFMT alone, pessary plus PFMT may slightly increase the risk of abnormal vaginal
bleeding and the risk of having diIiculty urinating, for women who did not have this problem before starting prolapse treatment, but the
evidence is very uncertain.
Certainty of the evidence
We assessed the evidence relating to pessary compared with no treatment as very low certainty because of the low numbers of women
participating in the study and because of problems with the way the trial was conducted. We assessed the evidence relating to pessary
compared with PFMT, and pessary plus PFMT compared with PFMT alone, as low- to moderate-certainty because of the low numbers of
women involved in the studies.
Authors' conclusions
Each of these trials contain small numbers of women, reducing the certainty of our conclusions. We are uncertain if pessaries improve pelvic
organ prolapse symptoms for women compared with no treatment or when compared to another active treatment like PFMT, but pessaries
in addition to PFMT probably improve women's symptoms and prolapse-specific quality of life. However, there may be an increased risk
of adverse events with pessaries compared to no treatment or PFMT.
The review found two economic evaluation studies that compared pessary treatment to alternative interventions (PFMT, expectant
management and surgical procedures).
Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Any pessary compared to control, waiting list or no active treatment
Any pessary compared to standard care
























Perceived resolution of prolapse symptoms: ≥ 12 months Not reported
Perceived improvement of prolapse symptoms (higher score = worse symp-
toms)















Prolapse-specific quality of life ≥ 12 months Not reported
Cure or improvement of sexual problems
assessed with: sex score of the Australian Pelvic Floor Questionnaire














Psychological outcome measures at ≥ 12 months Not reported
Number of women with adverse events (vaginal bleeding, voiding difficulty) Not reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; MD: mean difference; POP: pelvic organ prolapse; RCT: randomised controlled trial.
GRADE Working Group grades of evidence

















































































































































Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded one level for risk of bias (performance and attrition bias)
2 Downgraded two levels for imprecision (few participants and wide 95% CI crossing the line of no eIect)
 
 
Summary of findings 2.   Any pessary compared to pelvic floor muscle training (PFMT) for pelvic organ prolapse in women
Any pessary compared to PFMT or pelvic organ prolapse in women




Anticipated absolute effects* (95% CI)Outcomes
















Perceived resolution of prolapse symptoms ≥ 12 months Not reported
Women's perceived improvement of prolapse symp-
toms (higher score = worse symptoms)
assessed with: POPDI-6
Scale from: 0 to 100
Follow-up: 12 months
The mean POPDI-6 score in the
PFMT group was 16.4
MD 3.60 lower






Prolapse-specific quality of life (higher score = worse
QoL)
assessed with: PFIQ-7
Scale from: 0 to 300
Follow-up: 12 months
The mean PFIQ-7 score in the
PFMT group was 15.8
MD 3.3 higher






Cure or improvement of sexual problems (higher score =
better sexual functioning)
assessed with: PISQ-12,
Scale from: 0 to 48
Follow-up: 12 months
The mean PISQ-12 score in the
PFMT group was 37.6
MD 2.30 lower






















































































































































Psychological outcome measures at ≥ 12 months Not reported
Number of women with adverse events 21/35 women in pessary group and 0/62 women in PFMT group
experienced adverse events (14 increased vaginal discharge, 5
















*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; MD: mean difference;PFIQ: Pelvic Floor Impact Questionnaire; PISQ: Prolapse/Urinary Incontinence Sexual Questionnaire; POPDI-6: Pelvic Organ
Prolapse Distress Inventory 6; QI: quality of life; RCT: randomised controlled trial; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded two levels due to imprecision: few participants and wide 95% CI, consistent with possible benefit and possible harm
2 Downgraded two levels due to imprecision: few participants and few events, and the 95% CI suggests event rates that are implausibly wide
 
 
Summary of findings 3.   Pessary plus PFMT compared to pelvic floor muscle training (PFMT) alone for pelvic organ prolapse in women
Pessary plus PFMT compared to PFMT alone for pelvic organ prolapse in women
Patient or population: pelvic organ prolapse in women
Setting: urogynaecological clinic
Intervention: pessary plus PFMT
Comparison: PFMT alone





































































































































































Perceived improvement of prolapse symptoms
Follow-up: 12 months











Prolapse-specific quality of life
assessed with: POPIQ (higher score = worse quality of life) (scale: 0-100
Follow-up: 12 months
Median (IQR) scores:
Pessary + PFMT = 0.3 (0–22.2) (132








Cure or improvement of sexual problems ≥ 12 months Not reported
Psychological outcome measures at ≥ 12 months Not reported
Number of women with adverse events - abnormal vaginal bleeding
Follow-up: 12 months










Number of women with adverse events - de novo voiding difficulty
Follow-up: 12 months










*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; ; POPIQ: Pelvic Organ Prolapse Impact Questionnaire; RCT: randomised controlled trial; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
1 Downgraded one level for imprecision: few participants
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B A C K G R O U N D
Description of the condition
Pelvic organ prolapse is the descent of some part, or parts,
of the female pelvic organs (uterus, bladder and rectum) from
their normal anatomical position into the vagina. It aIects
about 40% of women aged over 40 (Hendrix 2002), with the
prevalence expected to increase as the population ages (Wu
2011). Pelvic organ prolapse includes anterior vaginal wall
prolapse (cystocoele, urethrocoele), posterior vaginal wall prolapse
(enterocoele, rectocoele, perineal deficiency), and uterine or
vaginal vault prolapse. Women can present with prolapse in one
or more of these sites. The International Continence Society has
standardised the naming of the condition using the POP-Q (Pelvic
Organ Prolapse Quantification) evaluation (Bump 1996), but in this
review we have also used the descriptive terms above as these are
compatible with literature searches.
The cause of pelvic organ prolapse is complex and multifactorial.
Various risk  factors have been proposed, including pregnancy,
childbirth, hereditary factors, denervation or weakness of the
pelvic floor, ageing, menopause, and factors associated with
chronically raised intra-abdominal pressure (such as obesity,
coughing and heavy liTing) (Bump 1998; Dietz 2008; Gyhagen 2015;
Jelovsek 2018; MacLennan 2000).
Women with prolapse may have a variety of pelvic floor
symptoms (Barber 2001; Hagen 2009; Jelovsek 2006; Lone 2011).
Women experience symptoms of 'something coming down', pelvic
heaviness, a dragging sensation in the vagina, a bulge, lump or
protrusion coming down from the vagina and backache. Women
can also experience symptoms related to the movement of
the pelvic organs and their protrusion into the vagina, which
include urinary symptoms, bowel symptoms and sexual diIiculties.
Symptoms, and perceived bother of symptoms, may negatively
aIect a woman's body image, quality of life and mental health, as
well as their ability to perform day to day activities (Jelovsek 2006;
Lowder 2011; Pakbaz 2010).
Description of the intervention
Prolapse treatment may be dependent on a number of factors,
including the severity of prolapse, the bother of the associated
symptoms, the woman's general health and the woman's
treatment preference (Basu 2011; Kapoor 2009). Various treatment
options exist for women who have pelvic organ prolapse and these
can be split into surgical and conservative options. Approximately
9.5% of women will undergo prolapse surgery in their lifetime
(Abdel-Fattah 2011). A US-based study forecast that approximately
9.2 million women will be aIected by pelvic organ prolapse by
2050 (Wu 2009), and about 300,000 women undergo pelvic organ
prolapse surgery in the USA every year costing over 1 billion US
dollars (the cost year was unclear) (Enemchukwu 2019; Subak
2001). The NHS spent over £45 million on the treatment of prolapse
between 2017 and 2018 (Primary Care Women's Health Forum
2019).
Vaginal pessaries are passive mechanical devices that are worn
internally and designed to support the vaginal walls and apex.
An extensive range of pessaries have been described for treating
prolapse (Oliver 2011; Poma 2000). These consist mainly of PVC,
latex or silicone pessaries, which are shaped devices inserted into
and leT inside the vagina to support the prolapsed pelvic organs.
Two main groups of pessaries are used: support pessaries (e.g. ring
pessary or ring pessary with support) and space filling pessaries
(e.g. Gellhorn or cube) (Dwyer 2019; Oliver 2011). Support pessaries
are inserted into the vagina and are positioned between the pubic
bone and posterior vaginal fornix, providing support to descending
organs. They do not prohibit vaginal intercourse and are easier
to remove and replace. Space filling pessaries provide support
by filling the vaginal space to prevent prolapse descent, creating
a suction eIect around the pessary which thereby increases the
likelihood of retention. They are not compatible with vaginal
intercourse and are more diIicult to remove and replace (Dwyer
2019). Studies suggest that ring pessaries are the most commonly
used in practice (Bugge 2013a; CundiI 2000).
Recently published NICE guidance suggests considering pessary
treatment (alone or with: pelvic floor muscle training (PFMT)) when
women have symptomatic prolapse (NICE 2019). Surveys suggest
that 87% to 98% of clinicians report using pessaries in their clinical
practice (Bugge 2013a; CundiI 2000; Gorti 2009; Pott-Grinstein
2001), while 77% of gynaecologists report using pessaries as a first-
line treatment for prolapse (CundiI 2000). Health professionals
(87.6%) report that they are most likely to fit pessaries in women
aged 60 or older and 98.8% would use a pessary for treatment
when a woman is unfit for surgery (Bugge 2013a). Evidence from
observational studies suggests that about 76% of women who
try a pessary continue to use it for at least four weeks and, of
those women who continue pessary use for more than four weeks,
86% continued to use the pessary for over five years (Lone 2011).
Furthermore, observational studies have shown that pessaries may
improve symptoms for women (Lamers 2011; Manchana 2012).
How the intervention might work
Pessaries are used in pelvic organ prolapse in order to physically
support the vaginal walls and the pelvic organs behind them. The
pessary is inserted into the vagina with a view to holding the
prolapsed organs, supporting the pelvic structures, and relieving
pressure on the bladder and bowel (Dumoulin 2017). Using a
pessary in the management of pelvic organ prolapse aims to
prevent the prolapse from becoming worse, as well as helping to
decrease the frequency or severity of symptoms of prolapse, and
averting or delaying the need for surgery (Oliver 2011).
Why it is important to do this review
The eIectiveness of surgical treatment options for prolapse are
reported in other Cochrane Reviews (Baessler 2018; Maher 2016a;
Maher 2016b; Maher 2016c; Mowat 2018). Conservative treatment
options that are currently used are pelvic floor muscle training
(PFMT), vaginal pessaries and lifestyle advice. The eIectiveness of
PFMT and lifestyle advice is reported in one review (Hagen 2011a).
The remaining conservative option, vaginal pessaries, is the focus
of this review.
The majority of evidence for the use of pessaries comes from non-
randomised studies (e.g. Brazell 2014; Clemons 2004b; Clemons
2004a; Clemons 2004c; Hanson 2006; Kapoor 2009; Lamers 2011;
Lone 2011; Manchana 2012). As such, the eIectiveness of pessaries
for managing pelvic organ prolapse still needs to be clearly
established. There is a lack of consensus as to the optimal
treatment for women. Provided that suIicient numbers of trials of
adequate quality have been conducted, the most reliable evidence
Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)
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is likely to come from consideration of randomised controlled trials
(RCTs), which is the basis for the current review. The aim is to help
identify optimal practice and highlight where there is a need for
further research.
Given that diIerent costs are associated with the alternative
interventions included in this review, it is important to conduct a
brief economic commentary (BEC) to find available evidence (if any)
on the costs of the interventions relative to their eIectiveness.
O B J E C T I V E S
To assess the eIects of pessaries (mechanical devices) for
managing pelvic organ prolapse in women; and summarise
the principal findings of relevant economic evaluations of this
intervention.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials (RCTs) and quasi-randomised trials
in which at least one arm was a pessary for pelvic organ prolapse.
We excluded cross-over studies.
Types of participants
We included studies focusing on adult women who were
seeking treatment for pelvic organ prolapse. Participants could
have prolapse with any POP-Q staging (Bump 1996), and
prolapse of any type: anterior vaginal wall prolapse (cystocoele,
urethrocoele); posterior vaginal wall prolapse (enterocoele,
rectocoele, perineal deficiency); and uterine or vaginal vault
prolapse. We included trials where women were seeking treatment
for urinary incontinence (UI) or prolapse if the data for women with
prolapse (including women with prolapse and UI) were considered,
or available separately.
Types of interventions
We included studies where one arm involved allocation to a pessary
aiming to provide support for pelvic organ prolapse. Thus, we
excluded studies where the pessary was used for exercise (and
not support) or where pessaries were only used to deliver drug
treatments (such as oestrogen). Pessaries could be of any type
and made of any material. The types of devices included support
pessaries (e.g. ring, ring with support) and space-filling devices (e.g.
shelf, Gellhorn, cube).
We considered the following comparisons and planned to present
'Summary of findings' tables for the first three.
• Any pessary versus control, waiting list or no active treatment.
• Any pessary versus another treatment (lifestyle interventions,
oestrogen treatment, physical interventions such as pelvic floor
muscle training, surgery).
• Any pessary plus another treatment versus the other treatment
alone.
• One pessary versus another pessary.
Types of outcome measures
Primary outcomes
• Women's perceived resolution of prolapse symptoms
• Women's perceived improvement in prolapse symptoms
(assessed using validated symptom questionnaires such as the
Pelvic Floor Disability Index (PFDI) (Barber 2001; Barber 2005),
or the Pelvic Organ Symptom Score (POP-SS) (Hagen 2009))
Secondary outcomes
• Patient-reported satisfaction with pessary treatment
• Grade of prolapse (i.e. the compartment that has the most
descent, e.g. using Pelvic Organ Prolapse-Quantification (POP-
Q) classification (Bump 1996))
• Site-specific grading of prolapse (i.e. the descent in each of the
specific anterior, apical or posterior compartments, e.g. using
POP-Q (Bump 1996))
• Prolapse-specific quality of life (measured with validated
instrument, e.g. the Pelvic Floor Impact Questionnaire (PFIQ),
Barber 2001; Barber 2005)
• Quality of life measured with generic quality of life or health
status measures (e.g. SF-36, Ware 1993)
• Psychological outcome measures (e.g. Hospital Anxiety and
Depression Scale (HADS), Zigmond 1983)
• Cure or improvement of bladder problems (including urinary
incontinence, occult incontinence and relief of voiding diIiculty)
• Cure or improvement of bowel problems (including relief of
obstructed defecation)
• Cure or improvement of sexual problems (including
acceptability of device to both partners)
• Number of women with adverse events (vaginal bleeding,
voiding diIiculty)
Timing of outcome assessment
We considered all outcomes at ≥ 12 months.
Main outcomes for 'Summary of findings' tables
These outcomes have been informed by a recent priority-setting
exercise for pessary use (Lough 2018).
• Woman's perceived resolution of prolapse symptoms at ≥ 12
months
• Woman's perceived improvement in prolapse symptoms
assessed using a validated symptom questionnaire at ≥ 12
months
• Prolapse-specific quality of life (e.g. PFIQ) at ≥ 12 months
• Cure or improvement of sexual problems at ≥ 12 months
• Psychological outcome measures at ≥ 12 months
• Number of women with adverse events (vaginal bleeding,
voiding diIiculty)
Search methods for identification of studies
We did not impose any language or other restrictions on any of the
searches detailed below.
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Electronic searches
Search for clinical eectiveness studies
We identified relevant trials from the Cochrane Incontinence
Specialised Register. For more details of the search methods
used to build the Specialised Register, please see the Group's
webpages where details of the Register's development (from
inception) and the most recent searches performed to populate the
Register can be found. To summarise, the Register contains trials
identified from the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead
of Print, ClinicalTrials.gov, WHO ICTRP, Be Part of Research and
handsearching of journals and conference proceedings. Many of the
trials in the Cochrane Incontinence Specialised Register are also
contained in CENTRAL.
The terms used to search the Cochrane Incontinence Group
Specialised Register are given in Appendix 1. The date of the most
recent search of the Register for this review: 28 January 2020.
The search methods and strategies used for some of the previous
versions of this review are given in Appendix 2.
Search for economic evaluations
We performed additional searches for the brief economic
commentary (BEC). We searched the following.
• The NHS Economic Evaluation Database (NHS EED) on the
Centre for Reviews and Dissemination (CRD) website (covering
from the earliest record in NHS EED, dating from 1968, up to and
including 31 December 2014 when their coverage ended). Date
of search: 13 February 2020.
As NHS EED is no longer actively updated, we performed additional
searches of the following databases to identify eligible studies
added to these databases from 1 January 2015 onwards (date of
search: 13 February 2020):
• MEDLINE on OvidSP (covering 1 January 1946 to January
February 1 2020); and
• Embase (on OvidSP) (covering 1 January 1974 to 2020 Week 06).
Details of the searches that were performed can be found in
Appendix 3.
Searching other resources
We searched the reference lists of relevant articles for other possibly
relevant trials. We also contacted the authors of included abstracts.
Data collection and analysis
We conducted data collection and analysis in accordance with
methods specified in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019).
Selection of studies
Two review authors independently screened all potentially eligible
abstracts from the search (CB and DG or MD). We nominated a third
review author to arbitrate in the event of disagreement (EJA). We
excluded any studies which were not relevant at this stage. We
then obtained the full-text articles of relevant studies. If there was
any uncertainty on the eligibility of the studies based on title and
abstract, we obtained the full paper, which was reviewed by the
same two review authors.
Data extraction and management
Two review authors independently undertook data extraction using
a predefined data extraction form (from CB, RK and FS). We
then made comparisons to ensure accuracy. We resolved any
discrepancies by discussion with, or referral to, a third party (EJA).
Assessment of risk of bias in included studies
We assessed the risk of bias within studies as part of the
data extraction. We used the methods outlined in the Cochrane
Handbook to assess risk of bias in the following domains
(Higgins 2011): random sequence generation (selection bias);
allocation concealment (selection bias); blinding of participants
and personnel (detection bias); blinding of outcome assessors
(performance bias); incomplete outcome data (attrition bias);
selective reporting (reporting bias); other bias not considered
under other domains. Two review authors assessed the included
studies for risk of bias and any discrepancies were resolved by
discussion and referred to a third author where necessary.
Measures of treatment e<ect
For binary outcomes, we have reported risk ratios (RR) and 95%
confidence intervals (CI). For continuous outcomes, we reported
mean diIerences (MDs) with 95% CIs.
Unit of analysis issues
The primary analysis was per woman randomised. Had data
allowed, we would have analysed each pair of arms in multi-arm
studies as a separate comparison. To avoid double-counting where
the same study with three treatment arms is included twice in the
same meta-analysis, we planned to divide the number of women
and events by two in the group that appears twice in the analysis.
Dealing with missing data
We contacted study authors to obtain missing data in order to
be able to conduct intention-to-treat analysis wherever possible.
Where randomised data were not available, we have reported data
from per protocol analyses as presented in the study publications.
We have clearly indicated in the EIects of interventions where we
have used per protocol data.
Assessment of heterogeneity
We intended to combine studies in meta-analysis where clinical
and methodological heterogeneity was low; that is, studies had
to be broadly similar in terms of participant characteristics,
interventions, study design and outcomes in order to be
pooled. Had data allowed, we would have assessed statistical
heterogeneity in meta-analyses as follows, taking into account the
magnitude and direction of eIects as well as the P value and/or
confidence interval for I2:
• 0% to 40%: heterogeneity might not be important
• 30% to 60% might represent moderate heterogeneity
• 50% to 90% might represent substantial heterogeneity
• 75% to 100% represents considerable heterogeneity
Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)
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Assessment of reporting biases
Using the data extraction form, we assessed for data that could
have been collected but was not reported. Where there were 10 or
more studies in the same meta-analysis and where data allowed,
we would have investigated reporting biases (such as publication
bias) using funnel plots. If funnel plot asymmetry was suggested
by a visual assessment, we would have performed exploratory
analyses to investigate it.
Data synthesis
Had data allowed, we would have used a fixed-eIect meta-
analysis for combining data if it was reasonable to assume that the
studies were estimating the same underlying treatment eIect (i.e.
where trials were examining the same intervention, and the trials’
populations and methods were judged suIiciently similar). If there
was clinical heterogeneity suIicient to expect that the underlying
treatment eIects diIered between trials, or if substantial statistical
heterogeneity was detected, we would have used a random-eIects
meta-analysis to produce an overall summary.
Subgroup analysis and investigation of heterogeneity
Had data allowed, we planned to carry out subgroup analysis
according to diIerent prolapse stages or compartments.
Sensitivity analysis
Had data allowed, we would have conducted sensitivity analyses to
examine the eIect of studies with high risk of bias on the results.
We would have repeated the main meta-analyses without studies
judged to be at high risk and compare those results to the main
analyses with all studies included.
Incorporating economics evidence
Once the search outlined in the Search methods for identification
of studies was performed, we developed a brief economic
commentary (BEC) to summarise the availability and principal
findings of the full economic evaluations that compared pessaries
with alternative treatment interventions for pelvic organ prolapse
in women (Shemilt 2019). This BEC encompassed full economic
evaluations (i.e. cost-eIectiveness analyses, cost-utility analyses
and cost-benefit analyses), conducted alongside or based on one or
more studies included in the main review of intervention eIects, or
model-based economic evaluations.
Summary of findings and assessment of the certainty of the
evidence
We prepared 'Summary of findings' tables using the GRADEpro
GDT soTware for the comparisons pre-stated in the Types of
interventions.
We used the GRADE approach to assess the certainty of evidence
related to the outcomes listed in the 'Main outcomes for 'Summary
of findings' tables' in the Types of outcome measures (Schünemann
2019). We used the five GRADE considerations (study limitations,
consistency of eIect, imprecision, indirectness and publication
bias) to assess the certainty of the body of evidence for the pre-
specified outcomes. We justified all decisions to downgrade the
certainty of studies using footnotes.
R E S U L T S
Description of studies
Results of the search
We reviewed 182 abstracts, of which 25 full-text reports (from
17 trials) were retrieved and assessed. Twelve reports of eleven
trials were subsequently excluded, which are detailed in the
Characteristics of excluded studies. Eleven reports of four studies
were included in the review. Additionally several studies were
identified within the search from their registration on clinical trial
databases, and from these we identified a further two studies that,
if completed, look likely to be included in future versions of this
review. These studies are reported in the Characteristics of ongoing
studies. The flow of literature through the assessment process for
the update of this review is shown in Figure 1.
 
Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)









Cochrane Database of Systematic Reviews
Figure 1.   PRISMA study flow diagram - search for clinical e<ectiveness studies
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This is the second review update. In the first version of the review,
no relevant randomised controlled trials (RCTs) were identified
(Adams 2004). In the first update (Bugge 2013b), we included
one cross-over study (CundiI 2007), which we have now excluded
because the cross-over study design means that we cannot tell
what the true eIects of the pessary are.
Searches for economic evaluations to inform the development
of the brief economic commentary (BEC) produced 479 unique
records aTer removal of duplicates. We retrieved the full-text of
seven articles that appeared to meet our eligibility criteria but
found that three of these did not include the correct population
and were therefore excluded; the remaining four reports of two
economic evaluations were included in this BEC. The flow of
literature through the assessment process is shown in Figure 2.
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Figure 2.   PRISMA study flow diagram - search for economic evaluations for the BEC
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Included studies
Four trials met the inclusion criteria. Full details are included in the
Characteristics of included studies.
Design
All four included trials were RCTs. In one trial only six women were
randomised before patient preference took priority and data were
not reported per randomised group (Coolen 2018). The data were
therefore not usable in the review.
Sample size
Sample sizes ranged from 34 (Baessler 2019) to 276 (Cheung 2016).
Setting
The included trials took place in the Netherlands (Coolen 2018;
Panman 2016), Hong Kong (Cheung 2016), and Germany (Baessler
2019).
Participants
The trials included 478 women and the mean age ranged from 30.4
(Baessler 2019) to 65.6 years (Panman 2016). The trials included
women with: stage I to III POP-Q symptomatic prolapse (Cheung
2016); stage II or greater symptomatic prolapse (Coolen 2018;
Baessler 2019); and prolapse at or beyond the hymen (Panman
2016). One trial included women who were in the immediate
postpartum period (Baessler 2019).
Length of follow-up
Follow-up in included trials ranged from six weeks (Baessler 2019)
to two years (Panman 2016).
Interventions
One trial compared pessary with standard care (no interventions
for six weeks postpartum) (Baessler 2019). Two trials compared
pessary with another treatment: one compared pessary with
pelvic floor muscle training (PFMT) (Panman 2016), while another
compared pessary with surgery (Coolen 2018). One trial compared
pessary plus PFMT versus PFMT alone (Cheung 2016).
Outcomes
None of the included trials reported the primary outcome
of resolution of prolapse symptoms. Three trials reported the
primary outcome of perceived improvement of prolapse symptoms
(Baessler 2019; Cheung 2016; Panman 2016).
The secondary outcomes reported in the trials were as follows.
• Grade of prolapse (Baessler 2019; Coolen 2018; Panman 2016)
• Site-specific grading of prolapse (Baessler 2019; Coolen 2018;
Panman 2016)
• Prolapse-specific quality of life (Baessler 2019; Cheung 2016;
Coolen 2018; Panman 2016)
• Quality of life measured with generic quality of life or health
status measures (Coolen 2018; Panman 2016)
• Cure or improvement of bladder problems (Baessler 2019;
Cheung 2016; Coolen 2018; Panman 2016)
• Cure or improvement of bowel symptoms (Baessler 2019;
Cheung 2016; Panman 2016)
• Cure or improvement of sexual problems (Baessler 2019; Coolen
2018; Panman 2016)
• Number of women with adverse events (Baessler 2019; Cheung
2016; Coolen 2018; Panman 2016)
None of the included studies reported data on patient-reported
satisfaction with pessary treatment or psychological outcome
measures.
Excluded studies
Eleven studies were excluded (see the Characteristics of excluded
studies). Of these, two were excluded because it was not possible
to separate the data for the women with prolapse from the data for
women with urinary incontinence (Meriwether 2015; Taege 2017).
A further seven trials were excluded because they investigated
pessary plus another treatment compared with pessary alone
(Chou 2013; Hagen 2011b; McDermott 2012; Propst 2015; Sanker
2013; Tontivuthikul 2016; Viravaidya 2012). These studies would
address the eIectiveness of adding the other treatment to pessary,
but it would not be evidence of the eIectiveness of the pessary
itself. Two studies were excluded because they did not use eligible
study designs (CundiI 2007; Danandeh 2019).
Risk of bias in included studies
See Figure 3 and Figure 4 for visual representations of the risk of
bias in the included trials. Risk of bias for each included study is
further detailed in the Characteristics of included studies.
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Baessler 2019 + + - + - + +
Cheung 2016 + + - + + + +
Coolen 2018 - + - ? ? ? +
Panman 2016 + + - - + + +
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Figure 4.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
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Three trials had a low risk of bias for random sequence generation
as they utilised remote computerised systems for randomisation
(Baessler 2019; Cheung 2016; Panman 2016). Coolen 2018 had a
high risk of bias as only 6/113 women in the study were randomised.
For the remaining women in this study, the patients' treatment
preference took priority.
Allocation concealment
All four trials had a low risk of bias for allocation concealment,
as they used remote systems and in blocks of variable size,
hence blinding the researchers to the possible treatment allocation
(Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016).
Blinding
Blinding of participants and personnel
All trials were unable to blind participants given the nature of the
interventions in use (pessaries, PFMT and surgery) (Baessler 2019;
Cheung 2016; Coolen 2018; Panman 2016). We therefore judged
them to be at high risk of performance bias since knowledge of their
assignment could influence their subjective assessment of their
prolapse symptoms.
Blinding of outcome assessment
We assessed two trials as low risk of detection bias (Baessler
2019; Cheung 2016) because assessors were blinded to group
allocation. One trial was judged to be at an unclear risk of bias
for this domain (Coolen 2018). One trial was judged at high risk of
detection bias because the outcome assessors were not blinded
to group allocation (Panman 2016). In all cases where it was
reported, attempts were made to blind the assessors to previous
measurements.
Incomplete outcome data
One trial was assessed as high risk of attrition bias because
of the substantially higher withdrawal rate in the control group
(Baessler 2019). Two trials were assessed to be at a low risk
of attrition bias because there was no diIerential attrition and
the trialists conducted intention-to-treat analysis (Cheung 2016;
Panman 2016). In one trial, the risk of attrition bias was unclear due
to a lack of information (Coolen 2018).
Selective reporting
Three trials were assessed as having a low risk of reporting bias
as all outcomes were reported across all the published material
(Baessler 2019; Cheung 2016 Panman 2016). The fourth trial did not
provide suIicient information to judge the risk of reporting bias and
so was judged to be at unclear risk of bias (Coolen 2018).
Other potential sources of bias
There were no indications of any other kind of bias in the included
trials, so all four were judged to be at low risk of bias (Baessler 2019;
Cheung 2016; Coolen 2018; Panman 2016).
E<ects of interventions
See: Summary of findings 1 Any pessary compared to control,
waiting list or no active treatment; Summary of findings 2 Any
pessary compared to pelvic floor muscle training (PFMT) for pelvic
organ prolapse in women; Summary of findings 3 Pessary plus
PFMT compared to pelvic floor muscle training (PFMT) alone for
pelvic organ prolapse in women
Any pessary versus control, waiting list or no active treatment
One trial compared a ring pessary versus standard care (defined as
no treatment for six weeks postpartum) for women who had stage II
prolapse one to three days postpartum (Baessler 2019). In this trial,
13 women were randomised to pessary care and 21 to standard
care.
Primary outcomes
Women's perceived resolution of prolapse symptoms
Not reported.
Women's perceived improvement in prolapse symptoms
Baessler 2019 measured improvement in prolapse symptoms using
the Australian Pelvic Floor Questionnaire (Baessler 2009). We are
uncertain if pessaries have any eIect on women's perceived
improvement in prolapse symptoms compared to standard care
(mean diIerence (MD) -0.03, 95% confidence interval (CI) -0.61 to
0.55; 1 study; 27 women; very low-certainty evidence; Summary of
findings 1; Analysis 1.1).
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Secondary outcomes




Site-specific grading of prolapse
Baessler 2019 measured site-specific grading of prolapse using the
POP-Q. ATer the pessary has been removed for a period of time, we
are uncertain if it has any eIect on the anatomical measurement
of prolapse compared with standard care (anterior compartment:
MD 0.10, 95% CI -0.73 to 0.93; 1 study, 27 women; Analysis 1.2;
posterior compartment (0.10, 95% CI -0.49 to 0.69; 1 study, 27
women; Analysis 1.3).
Prolapse-specific quality of life
Not reported.





Cure or improvement of bladder problems
Baessler 2019 measured bladder problems using the bladder score
of the Australian Pelvic Floor Questionnaire. We are uncertain if
pessaries have any eIect on bladder problems compared with
standard care (MD -0.15, 95% CI -0.55 to 0.25; 1 study, 27 women;
Analysis 1.4).
Cure or improvement of bowel problems
Baessler 2019 measured bladder problems using the bowel score
of the Australian Pelvic Floor Questionnaire. We are uncertain
if pessaries have any eIect on bowel problems compared with
standard care (MD 0.00, 95% CI -0.60 to 0.60;1 study, 27 women;
Analysis 1.5).
Cure or improvement of sexual problems
Baessler 2019 measured bladder problems using the sex score
of the Australian Pelvic Floor Questionnaire. We are uncertain if
pessaries have any eIect on curing or improving sexual problems
compared with standard care (MD -0.29, 95% CI -1.67 to 1.09;
1 study; 27 women; very low-certainty evidence; Summary of
findings 1; Analysis 1.6).
Number of women with adverse events (vaginal bleeding, voiding
di<iculty)
The adverse events of vaginal bleeding and voiding diIiculty were
not reported.
Any pessary versus another treatment
One trial compared a pessary with pelvic floor muscle training
(PFMT) (Panman 2016). In this trial, 82 women received a pessary
and 80 women received PFMT. Another trial compared a pessary
with surgery (Coolen 2018). However, of the 113 women recruited
to the trial only six consented to the randomisation process (two
were randomised to pessary and four to surgery). The data were
presented for the whole study population as a prospective cohort
and therefore were not usable for this review.
Primary outcomes
Women's perceived resolution of prolapse symptoms
Not reported.
Women's perceived improvement in prolapse symptoms
Panman 2016 measured improvement in prolapse symptoms using
the Pelvic Floor Disability Index (PFDI-20) (Barber 2005), and also
the subscale of the PFDI measure on specific prolapse symptoms
(Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6)). According
to POPDI-6 scores, we are uncertain if pessaries have any eIect on
women's prolapse symptoms compared with PFMT at 12 months
(MD -3.60, 95% CI -8.73 to 1.53; 117 women; Analysis 2.3; low-
certainty evidence Summary of findings 2), or at 24 months (MD
-4.20, 95% CI -9.03 to 0.63; 141 women; Analysis 2.4). According to
PFDI-20 scores at 12 months, we are uncertain if pessaries have any
eIect on women's prolapse symptoms compared with PFMT (MD
-9.60, 95% CI -22.53 to 3.33; 137 women; Analysis 2.1). At 24 months
the MD PFDI-20 was -12.10 (95% CI -25.33 to 1.13; 138 women;
Analysis 2.2).
Panman 2016 reported the number of women self-reporting 'better'
or 'much better' symptoms. At 24 months, we are uncertain if
pessaries have any eIect on women's perceived improvement in
prolapse symptoms compared with PFMT because the certainty of
evidence is low and the 95% CI spans possible harm and possible
benefit (risk ratio (RR) 1.01, 95% CI 0.64 to 1.59; 1 study; 142 women;
Analysis 2.5).
Secondary outcomes




Site-specific grading of prolapse
Not reported.
Prolapse-specific quality of life
Panman 2016 measured prolapse-specific quality of life using the
PFIQ-7. At 12 months' follow-up, we are uncertain if pessaries
have any eIect on prolapse-specific quality of life compared to
PFMT because the evidence is low certainty and the wide 95% CI
is consistent with possible harm and possible benefit (MD -3.30,
95% CI -8.70 to 15.30; 1 study; 116 women; low-certainty evidence;
Summary of findings 2; Analysis 2.6)
At 24 months' follow-up it is still uncertain if pessaries have any
eIect on prolapse-specific quality of life compared with PFMT (MD
-3.00, 95% CI -12.72 to 6.72; 133 women; Analysis 2.7).
Quality of life measured with generic quality of life or health status
measures
Panman 2016 measured general quality of life using the two
subscales of the SF-12 (Ware 1996) (physical health score (PCS-12);
mental health score (MCS-12)). The MD between groups for the
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PCS-12 at 12 months was 1.20 (95% CI -2.45 to 4.85; 108 women;
Analysis 2.8). The MD between groups for the PCS-12 at 24 months
was 2.30 (95% CI -1.01 to 5.61; 130 women; Analysis 2.9). The MD
between groups for the MCS-12 at 12 months was -1.90 (95% CI -5.58
to 1.78; 108 women; Analysis 2.10) and -1.70 at 24 months (95% CI
-4.67 to 1.27;130 women; Analysis 2.11).
Psychological outcome measures
Not reported.
Cure or improvement of bladder problems
Panman 2016 measured bladder symptoms using the Urinary
Distress Index (UDI-6) (a subscale of the PFDI-20). The MD between
groups at 12 months was -2.70 (95% CI -9.45 to 4.05; 115 women;
Analysis 2.12). At 24 months, the MD between groups was -2.20 (95%
CI -8.33 to 3.93; 140 women; Analysis 2.13).
Cure or improvement of bowel problems
Panman 2016 measured bowel problems using the Colorectal-Anal
Distress Inventory-8 (CRADI-8) (a subscale of the PFDI-20). The MD
between groups at 12 months was -3.50 (95% CI -8.61 to 1.61; 114
women; Analysis 2.14). At 24 months, the MD between groups was
-4.50 (95% CI -9.38 to 0.38; 141 women; Analysis 2.15).
Cure or improvement of sexual problems
Panman 2016 measured sexual function using PISQ-12. At 12
months' follow-up, pessaries may have a slightly detrimental eIect
on women's sexual function compared with PFMT (MD -2.30, 95%
-5.20 to 0.60; 1 study; 48 women; low-certainty evidence; Summary
of findings 2; Analysis 2.16).
At 24 months, we are uncertain if pessaries have any eIect on
women's sexual function compared with PFMT (MD -1.00, 95% CI
-3.49 to 1.49; 58 women; Analysis 2.17).
Number of women with adverse events (vaginal bleeding, voiding
di<iculty)
Data on complications in one study were only available as
part of the per protocol analysis (Panman 2016). Pessaries may
substantially increase the risk of adverse events compared with
PFMT (RR 75.25, 95% CI 4.70 to 1205.45; 1 study; 97 women; low-
certainty evidence; Summary of findings 2; Analysis 2.18). There
were no reported complications for the PFMT group. Of the 35
women who persisted with a pessary until 24 months, 60% (n =
21) reported pessary-related side eIects. These were: increased
vaginal discharge (n = 14); increased urinary incontinence (n = 5);
and irritation or erosions of the vaginal wall (n = 10).
Panman 2016 also reported reasons for pessary device removal. For
34 women, the initial pessary fit was unsuccessful, with a further
seven women then also experiencing unsuccessful fit. Twelve
women discontinued pessary treatment for the following reasons:
increased incontinence (n = 4); vaginal erosion (n = 2); pessary
treatment too burdensome (n = 2); no eIect of pessary treatment (n
= 1); discomfort during intercourse (n = 1); and other reasons (n = 3).
Any pessary plus another treatment versus the other
treatment alone
One trial compared pelvic floor muscle training (PFMT) plus a
pessary with PFMT alone (Cheung 2016). A total of 276 women
were randomised in this trial: 137 received PFMT treatment and 139
received PFMT treatment plus a vaginal pessary.
Primary outcomes
Women's perceived resolution of prolapse symptoms
Not reported.
Women's perceived improvement in prolapse symptoms
At 12 months, pessary plus PFMT probably leads to more women
perceiving improvement in their prolapse symptoms compared
with PFMT alone (RR 2.15, 95% CI 1.58 to 2.94; 1 study; 260 women;
moderate-certainty evidence; Summary of findings 3; Analysis 3.1).
With pessary plus PFMT, 32.3% more women will probably feel
that their symptoms have improved compared with pessary alone
(16.3% more to 54.6% more).
Cheung 2016 also measured perceived improvement in prolapse
symptoms using the PFDI questionnaire (and the POPDI subscale
- prolapse-specific symptoms; Barber 2001). In the intention-to-
treat ( ITT) analysis, there was a diIerence at 12 months for the
POPDI subscale of the PFDI for women undertaking PFMT plus
pessary (median score 32.1, interquartile range (IQR) 12.5 to 78.6;
139 women) compared to those in the PFMT-only group (median
score 49.4, IQR 21.4 to 95.2; 137 women; P = 0.04), which further
suggests that a pessary may improve prolapse symptoms when
added to PFMT.
Secondary outcomes




Site-specific grade of prolapse
Not reported.
Prolapse-specific quality of life
In Cheung 2016, at 12 months the women's prolapse-specific
quality of life was measured using the POPIQ subscale of the PFIQ
(higher score = worse quality of life; Barber 2001). On POPIQ score,
pessary plus PFMT probably improves women's prolapse-specific
quality of life (median 0.3, IQR 0 to 22.2; 132 women, in comparison
to the PFMT-only group (median 8.9, IQR 0 to 64.9, 128 women; P =
0.02; moderate-certainty evidence; Summary of findings 3).





Cure or improvement of bladder problems
Cheung 2016 reported the number of women with pre-existing
bladder problems who reported their symptoms had improved.
Compared with PFMT alone, more women in the pessary plus
PFMT group perceived cure or improvement of stress urinary
incontinence (SUI) (19/82 and 15/70 respectively; RR 1.08, 95% CI
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0.60 to 1.96; 152 women; Analysis 3.2) and cure or improvement
of voiding diIiculty (25/40 and 11/31 respectively; RR 1.76, 95% CI
1.03 to 3.00; 71 women; Analysis 3.4). Fewer women in the pessary
plus PFMT group perceived cure or improvement in urgency
urinary incontinence compared with PFMT alone 17/59 and 18/44
respectively; (RR 0.70, 95% CI 0.41 to 1.20; 103 women; Analysis 3.3).
In the 12-month ITT analysis, Cheung 2016 also measured urinary
symptoms using the UDI and associated quality of life using the
Urinary Impact Questionnaire (UIQ).
• Median (IQR) UDI score: pessary plus PFMT 39.4 (16.9 to 74.7),
132 women; PFMT-only 37.5 (16.7 to 67.5), 128 women; P = 0.57
• Median (IQR) UIQ score: pessary plus PFMT13.3 (0 to 40.3), 132
women; PFMT-only 9.7 (0 to 54.8), 128 women; P = 0.71
Cure or improvement of bowel problems
In the 12-month ITT analysis, Cheung 2016 measured bowel
symptoms using the CRADI and associated quality of life using the
CRAIQ.
• Median (IQR) CRADI score: pessary plus PFMT 32.1 (15.8 to 75.5),
132 women; PFMT-only 32.1 (14.9 to 68.0), 128 women; P = 0.80
• Median (IQR) CRAIQ score: pessary plus PFMT 0 (0 to 5.6), 132
women; PFMT-only 0 (0 to 5.6), 128 women; P = 0.77
Cure or improvement of sexual problems
Not reported.
Number of women with adverse events (vaginal bleeding, voiding
di<iculty)
Pessary plus PFMT may slightly increase the risk of abnormal
vaginal bleeding compared with PFMT alone (RR 2.18, 95% CI 0.69
to 6.91; 1 study; 260 women; low-certainty evidence; Summary of
findings 3; Analysis 3.5). Pessary plus PFMT may lead to 3.7% more
women having abnormal vaginal bleeding compared with PFMT
alone (1% fewer to 18% more).
We are less certain if pessary plus PFMT has any eIect on the risk of
de novo voiding diIiculty because the 95% CIs are wide and span
possible harm and possible benefit (RR 1.32, 95% CI 0.54 to 3.19; 1
study; 189 women; low-certainty evidence; Analysis 3.6; Summary
of findings 3).
One pessary versus another pessary
No trials were identified for this comparison.
D I S C U S S I O N
Summary of main results
Four trials involving a total of 478 women were included in this
updated review. None of the included trials reported our primary
outcome of women's perception of cure of prolapse symptoms. Due
to the varied nature of the comparisons, it was not possible to pool
data.
The evidence is very uncertain about the eIect of pessaries
compared with standard care on perceived improvement of
prolapse symptoms, prolapse-specific quality of life, and cure or
improvement of sexual problems (Summary of findings 1). We did
not find any evidence about the risk of adverse events compared
with standard care (no treatment).
We are uncertain whether pessaries have any eIect on women's
perceived improvement in prolapse symptoms compared with
pelvic floor muscle training (PFMT). We are also uncertain whether
pessaries have any eIect on prolapse-specific quality of life
measured with the Pelvic Floor Impact Questionnaire-7 (PFIQ-7),
or on cure or improvement of sexual problems measured with the
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire
(PISQ-12) compared with PFMT (low-certainty evidence). However,
pessaries may result in a large increase in risk of adverse
events compared with PFMT (low-certainty evidence). Adverse
events included increased vaginal discharge, increased urinary
incontinence and erosion or irritation of the vaginal walls
(Summary of findings 2).
Pessary plus PFMT probably leads to more women perceiving
improvement in their prolapse symptoms and in their prolapse-
specific quality of life compared with PFMT alone (moderate-
certainty evidence). However, pessary plus PFMT may slightly
increase the risk of abnormal vaginal bleeding compared with PFMT
alone (low-certainty evidence). We are less certain if pessary plus
PFMT has any eIect on the risk of de novo voiding dysfunction
because the 95% CIs are wide and span possible harm and possible
benefit (Summary of findings 3).
Overall completeness and applicability of evidence
We identified no studies comparing diIerent types of pessaries.
The studies included here are small and do not report several of
our outcomes of interest. In particular, we identified no evidence
regarding the eIect of pessaries on women's perceived resolution
of prolapse symptoms. However, the women included in the studies
are largely representative of the wider population of women with
pelvic organ prolapse in that they represent women with prolapse
of diIerent types, stages and across a range of ages.
Although the evidence base about vaginal pessary use for
pelvic organ prolapse in women is growing, the available trials
oIer limited answers to the primary question regarding the
eIectiveness of pessaries in resolving or improving women's
prolapse symptoms. In addition, we do not have adequate evidence
to be certain regarding the eIect of pessaries on quality of life, or
their complications and adverse eIects.
Quality of the evidence
Overall, we judged the studies to have a low risk of bias in most
domains. Given that it was not possible to blind participants to
their treatment allocation in any of the studies, and given that our
primary outcome is subjectively reported, we judged the studies to
have a high risk of performance bias. Due to imbalanced attrition
and missing outcome data, we also judged some studies to have a
high risk of attrition bias.
With regard to the outcomes presented in the 'Summary of findings'
tables, we made decisions to downgrade the certainty of evidence
because of the extent of risk of bias. Additionally, we downgraded
all outcomes for imprecision due to the small sample sizes in the
studies.
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Potential biases in the review process
We made every attempt to reduce bias in the review as far as
possible, with broad inclusion criteria and a comprehensive search
strategy not limited by language or publication type. We also
ensured data extraction and 'Risk of bias' assessments were carried
out independently by two review authors.
Brief economic commentary
In addition to the main review, we searched for economic
evaluations that compared pessaries with either surgical
procedures or conservative management, or both. From searches
conducted in February 2020, we identified two economic
evaluation studies (Hullfish 2011 and Panman 2016). We did not
subject these identified economic evaluations to critical appraisal
and we do not attempt to draw any firm or general conclusions
regarding the relative costs or eIiciency of pessaries in treating
pelvic organ prolapse.
Hullfish 2011 conducted a model-based cost-utility analysis (CUA)
comparing expectant management, placement of a pessary
and surgical procedures (vaginal reconstructive surgery (VRS),
traditional/open abdominal sacrocolpopexy, and robotic-assisted
abdominal sacrocolpopexy) for post-hysterectomy pelvic organ
prolapse. The study was conducted in the USA. A Markov model was
developed to link potential health states and probabilistic events
that follow from each treatment strategy. The model inputs include
event probabilities, costs and utilities for outcomes at "a baseline
case of a healthy 65 year old, post-hysterectomy female with ≥
stage III apical prolapse of the vagina, who wishes to preserve
coital function". Event probabilities were mainly obtained from a
review of published literature but expert knowledge was used to
derive missing estimates. Due to the unavailability of health-related
quality of life utility scores for pelvic organ prolapse, the authors
used relative utility values that were developed based on clinical
researchers' opinions. The model structure allows individuals to
exist in one of seven health states during any given month over
a 12-month period. These health states include pelvic organ
prolapse with no complications, with presenting complications
(voiding dysfunction); pessary with no complications, pessary with
complication (vaginal erosion); repaired pelvic organ prolapse
without late/postoperative complications (urinary tract infection);
and repaired pelvic organ prolapse with major late complications
(i.e. reoperation). Only direct medical costs of each treatment
alternative were estimated from a number of sources for the
analysis. The currency and price year are US $ and 2007
respectively. At baseline, only pessary and VRS were found to
be cost-eIective: pessary use yielded about 10.4 quality-adjusted
months at a cost of $10,000 per patient and the VRS alternative
obtained 11.4 quality-adjusted months at a cost of approximately
$15,000 per patient.
In a deterministic sensitivity analysis, expectant management
with VRS was eIicient when baseline probability of pelvic
organ prolapse complications was decreased. Pessary alternative
was no longer eIicient aTer the probability of pelvic organ
prolapse complications was reduced to 0.12 and the probability
of surgery following pessary use was increased to 0.17. Monte
Carlo simulation results indicated that pessary use was an optimal
alternative below $5600 ‘Willingness to Pay’ (WTP) per quality-
adjusted life month threshold and VRS was the optimal strategy
above that threshold. The authors concluded that their model
demonstrated that pessary use and VRS are both cost-eIective
alternatives for treating hysterectomy vaginal prolapse given the
context of their study.
Panman 2016 conducted both a CUA and a cost-eIectiveness
analysis (CEA) to compare pessary treatment with pelvic floor
muscle training (PFMT) using RCT data (three follow-ups within
two years) from 20 primary care practices in the Netherlands
(Wiegersma 2014). Participants included all women aged at least
55 years registered with their primary care practice. The outcome
used in the CEA was distress measured by Pelvic Floor Distress
Inventory-20 (PFDI-20; Barber 2005), while quality-adjusted life-
years (QALYs) were measured in the CUA based on EQ-5D utility
values using the UK population tariI (Dolan 1995). Only direct
medical costs were included in the analysis, with a time horizon
of two years. The main costs of the intervention included
pessaries and pessary-related visits, costs of physical therapy,
consultations with GPs and medical specialists, use of absorbent
pads, medication and costs of operative procedures. Both costs
and health benefits were recorded and estimated on an individual
participant basis, and then the mean diIerences of eIects and costs
between the two treatment groups were estimated. The costs were
valued in Euros at 2014 price level and later converted to US dollars
based on the November 24 2015 exchange rate (1 Euro = 1.0657
dollars). Results of the analysis were summarised in incremental
cost-eIectiveness ratio (ICER) and incremental cost-utility ratio
(ICUR) for the CEA and CUA respectively. However, the focus is
on the results of the cost-eIectiveness planes which, as indicated
below, show the likelihood that an intervention was less costly but
more eIective.
The costs per person were $309 in the pessary group and $437 in the
PFMT group. The mean diIerence was $128 (95% CI 27 to 236), with
costs dependent on the primary treatment. Costs for pessaries and
pessary-related visits were higher in the pessary group ($202 per
person compared with $0.5 in the PFMT group), whereas costs for
physical therapy were higher in the PFMT group ($324 per person
for the PFMT group compared with $2 in the pessary group).
In the CUA, both treatment groups lost QALYs over the study period,
with slightly less lost in the pessary group (0.024 in the pessary
group and 0.065 in the PFMT group). In total, 71% of the 5000
replications in the bootstrap simulation indicated better outcomes
and lower costs for the pessary group.
The authors stated that there was no diIerence in change in pelvic
floor symptoms between pessary treatment and PFMT in women
aged 55 years or older recruited by screening. Although pessary
treatment led to a statistically significant greater improvement in
typical prolapse symptoms compared with PFMT, the diIerence
was small and the clinical relevance doubtful.
The authors reported that their study was the first to investigate
the cost-eIectiveness of pessary treatment and PFMT from such a
trial and that there were no significant diIerences between pessary
treatment and PFMT in the reduction of pelvic floor symptoms but
women with apex prolapse symptoms benefited more from pessary
treatment than from PFMT. Pessary treatment was preferable to
PFMT in the cost-eIectiveness analysis, with PFMT being more
expensive but no more eIective.
The interventions compared in one of the economic evaluation
studies match interventions compared in Summary of findings
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2 (Panman 2016). It would therefore be useful to compare the
findings of the economic evaluation with data in Summary of
findings 2.
End users of this review will need to assess the extent to which
results of identified economic evaluations may be applicable (or
transferable) to their own setting.
Agreements and disagreements with other studies or
reviews
The previous version of this review (Bugge 2013b), the most
recent review for the International Continence Society monograph
(Dumoulin 2017), and the current review have all reached similar
conclusions. All conclude that there is insuIicient evidence on
which to guide clinical practice surrounding prolapse management
using vaginal pessaries.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The evidence from randomised controlled trials (RCTs) on which
to base the treatment of women with pelvic organ prolapse
using vaginal pessaries remains very limited. The research base is
growing but more trials are needed in order for data to be pooled
in a way that will allow for greater certainty in recommendations
for treatment. Clinical staI may wish to read this review alongside
the surgical Cochrane Reviews (Baessler 2018; Maher 2016a; Maher
2016b; Maher 2016c; Mowat 2018) and the Cochrane Review of
conservative and lifestyle measures (Hagen 2011a).
In the postpartum period, one small trial compared pessary versus
standard care (no treatment for six weeks), and across the available
comparisons the certainty of evidence was very low, making
recommendations for practice in the postpartum period diIicult.
Panman 2016 compared pessary versus pelvic floor muscle training
(PFMT), and it was uncertain if pessary had an eIect on women's
perceived improvement in prolapse symptoms in comparison to
PFMT. Both PFMT and pessary are active treatments and, as such, it
is not known if improvements were greater than if no treatment had
been given. Cheung 2016 added a pessary to PFMT and probably led
to more women perceiving an improvement in prolapse symptoms.
It may be that practitioners consider the added benefit of a pessary
for women with prolapse who are receiving PFMT.
There was some evidence of an increase in adverse events with
pessary use. However, the clinical significance of these adverse
events is unknown but may be argued to be low. Specifically,
increased vaginal bleeding and discharge may be adverse events
a woman is willing to accept if she experiences a decrease in
prolapse symptoms. De novo stress urinary incontinence (SUI)
may be a more problematic adverse event for women, but the
evidence surrounding the eIects of pessary on de novo SUI are not
certain. While some evidence is suggestive of an increase in adverse
events for women who use a pessary for prolapse, the extent to
which these events are bothersome for women requires further
investigation before recommendations can be made for practice.
Implications for research
Adequately-powered trials measuring clinically-important
outcomes are urgently needed to guide international practice. The
comparison between pessary and no active treatment is perhaps
diIicult as there is observational evidence suggesting benefit of
pessary and other conservative treatments, making a no active
treatment group possibly unacceptable to women or policy makers
(Hagen 2011a; Lamers 2011).
Across the other comparisons more research is needed, specifically:
pessary versus another active treatment; pessary as an adjunct
to other treatments; and comparison between pessary types.
It is important that future trials measure women's perceived
resolution of prolapse symptoms. Qualitative research about the
bothersomeness of adverse events of pessary use would also
support the understanding of adverse event reporting in the trials.
As the evidence base evolves, it will also be helpful to explore the
eIectiveness of pessary for diIerent stages and types of prolapse.
This review identified only two relevant economic evaluations,
which highlights both the lack of economic evidence and the need
to conduct more economic evaluations on prolapse interventions
that includes pessaries.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Design: two-arm parallel RCT
Participants Country: Germany
Number of participants: 34
Mean age: pessary group 32 (SD 5.6); standard care 30.4 (SD 6.6)
Prolapse staging: stage II
Prolapse compartment: anterior and posterior
Inclusion criteria: women 18 and over, first vaginal delivery, stage 2 POP (examination or perineal ul-
trasound in standing position)
Baessler 2019 
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Exclusion criteria: severe diseases of mother/child, previous pelvic surgery, neurological diseases, se-
vere perineal post partum pain, high vaginal tears
Interventions Group I (n = 13): vaginal ring pessary
Group II (n = 21): standard care (no interventions for six weeks postpartum)
Outcomes Primary outcome: prolapse symptoms measured using the Australian Pelvic Floor Questionnaire (Ger-
man version with validated postpartum module) at 12 months
Secondary outcomes: POP-Q, pelvic ultrasound for bladder neck and puborectalis at rest and on
straining in standing
Notes Funding source: not reported
Declarations of interest: J Stupin discloses Arabin GmbH: Consultant, all other authors state they
have noting to disclose.
Trial stopped early due to poor recruitment and 'occasional pessary problems which were solved with
pessary removal'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk PC-generated randomisation list put into opaque envelopes. Preference was
permitted but data are available for randomised group only
Allocation concealment
(selection bias)





High risk Not possible to blind participant or caregiver.
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Data provided on measured outcomes.





Methods Design: parallel group RCT
Dates study conducted: December 2011 to November 2014
Cheung 2016 
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Participants Setting: Hong Kong, single centre
Number of participants: 276 women with pelvic organ prolapse stages I to III (POPQ)
Mean age: PFMT group 62.7 (SD 10.2); pessary group 62.5 (SD 9.1)
Prolapse staging:
PFMT group: stage I n = 14 (10%); stage II n = 92 (67%); stage III n = 31 (23%)
Pessary group: stage I n = 11 (8%), stage II n = 96 (69%) stage III n = 32 (23%)
Prolapse compartment:
PFMT group: anterior n = 91 (61.4%); apical n = 38 (27.7%); posterior n = 8 (5.8%)
Pessary group: anterior n = 90 (64.7%); apical n = 45 (32.4%); posterior n = 4 (2.9%)
Inclusion criteria: symptomatic pelvic organ prolapse stage I to III (POP-Q), no previous treatment
Exclusion criteria: complications that arise from prolapse, confirmed urinary retention, vaginal ero-
sion or ulcer that required active treatment, impaired mobility, cognitive impairment, language barrier
that prevented questionnaire completion
Interventions Group I (n = 137): PFMT treatment alone
Group II (n = 139): vaginal ring pessary plus conservative treatment
Outcomes Primary outcome: PFDI and PFIQ plus subscales
Secondary outcome: discomfort from prolapse symptoms (VAS score), desired treatment, complica-
tions
Notes Funding source: not reported
Declarations of interest: quote: "The authors did not report any potential conflicts of interest"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Women randomised using random computer-generated numbers and allocat-
ed in serially numbered envelopes.
Allocation concealment
(selection bias)





High risk Participants not blinded to treatment. Investigator who took history and
recorded POP-Q blinded to group allocation.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Primary outcome self-completion. Investigator who took history and recorded




Low risk 135/139 in pessary group and 130/137 in PFMT alone group completed mea-
sures at 12 months.
Cheung 2016  (Continued)
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Selective reporting (re-
porting bias)
Low risk Not all outcomes listed in Trial registry and paper presented but main out-
comes are presented and they have reported outcomes of interest to this re-
view





Methods Design: parallel group RCT
Dates study conducted: June 2009 and July 2014
Participants Setting: single centre
Country: the Netherlands
Number of participants: 113 women
Mean age: not reported for randomised group (for cohort 63 years for pessary group; 58 surgical group
- pessary group significantly older)
Prolapse staging: not reported for randomised group
Inclusion criteria: symptomatic prolapse POP-Q stage II or greater, with bothersome urogynaecologi-
cal symptoms who wanted to undergo treatment
Exclusion criteria: previous prolapse or incontinence surgery, previous pessary treatment, patients in
whom surgery was contraindicated, isolated rectocele without prolapse in any other compartment
Interventions Group I (n = 74): pessary: Portex, Falk
Group II (n = 39): prolapse surgery: vaginal hysterectomy; anterior colporrhaphy; posterior colporrha-
phy; a combination of these surgical treatments; a combination of these surgical treatments including
MESH material.
Two randomised to pessary and four to surgery. All other women chose treatment by preference (72
pessary, 35 surgery).
Outcomes Primary outcome: disease-specific quality of life - prolapse domain of Urinary Distress Inventory (UDI)
Secondary outcomes: general quality of life (werkgroepbekkenbodem, EURQOL, SF36); successful
continuous pessary treatment; anatomical outcome (POP-Q).
Notes Funding source: not reported
Declarations of interest: not reported
Data on the six randomised women were not available in the published study reports. We were in com-
munication with the trialists regarding obtaining these data but the global pandemic of 2020 meant
we had to pause this process - we will re-establish contact with the trialists for the next review update
(Bugge 2020 [pers comm].
Risk of bias
Bias Authors' judgement Support for judgement
Coolen 2018 
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Random sequence genera-
tion (selection bias)
High risk Only six women randomised, patient preference took priority.
Allocation concealment
(selection bias)





High risk Blinding not possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Not known for randomised group
Selective reporting (re-
porting bias)
Unclear risk Not known for randomised group





Methods Design: parallel group RCT
Dates study conducted: October 2009 to December 2012
Participants Setting: multicentre (women recruited from 20 general practices)
Country: the Netherlands
Number of participants: 162 women with prolapse at or beyond hymen (POP-Q measured)
Mean age: PFMT group 65.6 (SD 6.4); pessary group 64.9 (SD 7.4)
Prolapse staging:
PFMT group: stage II 77.5% (n = 62); stage III 22.5% (n = 18).
Pessary group: stage II 70.7% (n = 58); stage III 29.3% (n = 24).
Prolapse compartment:
PFMT group: anterior 31.3% (n = 25), posterior 3.8% (n = 3), apical 0% (n = 0), anterior and posterior
32.5% (n = 26), anterior and apical 10% (n = 8), posterior and apical 2.5% (n = 2), anterior and posterior
and apical 20% (n = 16)
Pessary group: anterior 24.7% (n = 20), posterior 0% (n = 0), apical 0% (n = 0), anterior and posterior
28.4% (n = 23), anterior and apical 23.5% (n = 19), posterior and apical 0% (n = 0), anterior and posterior
and apical 23.5% (n = 19)
Inclusion criteria: women aged 55 years and older, GP registered, self-identified prolapse symptoms
(using screening tool), prolapse at or beyond hymen using POP-Q
Panman 2016 
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Exclusion criteria: current prolapse treatment (or within the last year for PFMT, pessary or surgery),
current treatment for gynaecological or urological disorder, current gynaecological or urological malig-
nancy, severe/terminal illness, inability to visit GP office, cognitive impairment, inability to understand
complete Dutch questionnaires, stage IV prolapse
Interventions Group I (n = 80): PFMT. Delivered by a registered pelvic physiotherapist registered with Dutch Pelvic
Physio Association. Started with explanation of pelvic floor function, if unable to contract taught this
first, women did exercises during physiotherapy contact and at home three to five times a week and
two to three times a day. All participants started with same exercise regimen and then individual adap-
tation in line with normal practice (included being able to use electrical stimulation). All taught the
knack. Attention paid to lifestyle and toileting habits. At three-month follow-up all PFMT group re-
ceived a leaflet with information and advice on lifestyle and continuing PFMT.
Group II (n = 82): pessary. Fitted by quote: "trained research physician" (n = 4). Two-week trial of pes-
sary with refit at two weeks if necessary (maximum of three refits); first ring, then ring with support and
then Shaatz or Gellhorn (all silicone). Follow-up started as soon as successful fit achieved. Additional
visits (to GP or research physician) to clean pessary and monitor side effects every three months. Topi-
cal oestrogen used for vaginal decubitus.
Outcomes Primary outcome: distress caused by pelvic floor symptoms measured by PFDI-20
Secondary outcomes: three subscales of PFDI-20, condition-specific and general quality of life, sexu-
al function, pelvic floor muscle function, POP-Q, post void residual volume, patients' perception of im-
provement, costs
Notes Funding source: quote: "funded by the Netherlands Organisation for Health Research and Develop-
ment (ZonMw), project number 4201.1001"; "The funding organization had no role in the design and
conduct of the study; the collection, management, analysis, and interpretation of the data; the prepa-
ration, review, or approval of the manuscript; or the decision to submit the manuscript for publica-
tion."
Declarations of interest: quote: "The authors declare no conflict of interest."
There is both the main paper that presented an intention-to-treat and per protocol analysis. The full
trial protocol is published (Panman 2016) .Data for intention-to-treat analysis available in main paper,
plus one conference abstract about the completed case analysis at three months (those with unsuc-
cessful pessary fitting excluded).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised in a 1:1 ratio using external (remotely accessed) computerised
system in variable block size
Allocation concealment
(selection bias)
Low risk Enrolling physician blind to block size and allocation sequence. Allocation us-





High risk Patients and treating health professionals not blinded to treatment allocation.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Research physicians were not blinded to allocation and outcomes may have




Low risk 70/80 in PFMT group and 74/82 in pessary group at 24 months
Panman 2016  (Continued)
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Selective reporting (re-
porting bias)
Low risk Data are presented across outcomes
Other bias Low risk None
Panman 2016  (Continued)
GP: general practitioner
PFDI-20: Pelvic Floor Disability Index
PFIQ: Pelvic Floor Impact Questionnaire
PFMT: pelvic floor muscle training
POP: pelvic organ prolapse
POP-Q: Pelvic Organ Prolapse Quantification
RCT: randomised controlled trial
SD: standard deviation
SF36: Short Form 36
UDI: Urinary Distress Index
VAS: visual analogue scale
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Chou 2013 Ineligible comparison
Cundiff 2007 Ineligible study design (cross-over RCT)
Danandeh 2019 Ineligible study design (not RCT)
Hagen 2011b Ineligible comparison
McDermott 2012 Ineligible comparison
Meriwether 2015 Not possible to separate data for women who had prolapse or prolapse plus incontinence from
women who had incontinence alone
Propst 2015 Ineligible comparison
Sanker 2013 Ineligible comparison
Taege 2017 Not possible to separate data for women who had prolapse or prolapse plus incontinence from
women who had incontinence alone
Tontivuthikul 2016 Ineligible comparison
Viravaidya 2012 Ineligible intervention
RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Polyvinyl chloride ring pessary versus silicon irregular hexagon pessary for pelvic organ prolapse: a
randomised trial comparing treatment success.
Methods Design: parallel RCT
Cornish 2018 
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Participants The study aims to recruit 104 women.
Inclusion criteria: women who are at least 18 years of age with symptomatic pelvic organ pro-
lapse, able to speak and read English, no previous use of a vaginal pessary for prolapse, at least
stage II prolapse for any single compartment or multi-compartment prolapse, willing to use a ring
pessary, willing and able to complete questionnaires and follow-up visits.
Exclusion criteria: refusal to participate, unable to speak or read English, women under 18 years
of age, previous vaginal pessary use, prior prolapse surgery, contraindications to topical oestrogen
therapy, unwilling to use a vaginal pessary, unable and unwilling to complete questionnaires and
attend follow-up visits.
Interventions Group I: a silicon irregular hexagonal pessary
Group II: PVC ring pessary
Outcomes Primary outcome: treatment success (defined as retention of the pessary at 6 months and 12
months post randomisation)
Secondary outcomes: self-reported ability to self-care at 6 and 12 months; satisfaction with pes-








Study name Pessary or prolapse surgery for symptomatic pelvic organ prolapse (PEOPLE)
Methods Multicentre pragmatic cohort study with an embedded randomised controlled non-inferiority trial
comparing pessary therapy versus surgery including an economic evaluation
Participants The aim is to recruit 436 women.
Inclusion criteria: women with prolapse stage 2 or more, women with moderate to severe pro-
lapse symptoms (score of > 33 on PFDI-20), women with successful pessary fitting, written in-
formed consent
Exclusion criteria: prior urogynaecological (prolapse or incontinence) surgery, probability of fu-
ture childbearing, insufficient knowledge of Dutch language, comorbidity causing increased surgi-
cal risks (at surgeon discretion), major psychiatric illness, prior pessary use
Interventions Group I: pessary
Group II: vaginal prolapse surgery
Outcomes Primary outcome: global impression of improvement of prolapse symptoms at 24 months (PGI-I)
Secondary outcome: change in symptom bother and disease-specific quality of life at 12 and 24
months, changes in sexual function at 12 and 24 months, changes in general quality of life at 3, 6,
12 and 24 months, adverse events/complications, development of prediction model to identify fac-
tors for failing of pessary and surgery, cost-effectiveness analysis
van de Waarsenburg 2014 
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Starting date 2015
Contact information C.H.vanderVaart@umcutrecht.nl
Notes This trial is ongoing.
van de Waarsenburg 2014  (Continued)
EQ-5D: EuroQol-5D
PFDI-20: Pelvic Floor Disability Index
PGI-I: Patient Global Impression of Improvement
PISQ-12: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire
PVC: polyvinyl chloride
RCT: randomised controlled trial
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Any pessary versus control, waiting list or no active treatment







1.1 Women's perceived improvement in prolapse symptoms: POP
score of Australian Pelvic Floor Questionnaire at 12 months (range
0-10, higher score = worse symptoms)




1.2 Site-specific grading of prolapse - anterior - (measured with POP-
Q) at 12 months




1.3 Site-specific grading of prolapse - posterior - (measured with
POP-Q) at 12 months




1.4 Cure or improvement of bladder problems at 12 months (mea-
sured with bladder score of Australian Pelvic Floor Questionnaire,
range 0-10, higher score = worse symptoms)




1.5 Cure or improvement of bowel problems at 12 months (measured
with bowel score of Australian Pelvic Floor Questionnaire, range 0-10,
higher score = worse symptoms)




1.6 Cure or improvement of sexual problems at 12 months (mea-
sured with sex score of Australian Pelvic Floor Questionnaire, range
0-10, higher score = worse symptoms)
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Analysis 1.1.   Comparison 1: Any pessary versus control, waiting list or no active treatment,
Outcome 1: Women's perceived improvement in prolapse symptoms: POP score of Australian


















IV, Fixed, 95% CI
-0.03 [-0.61 , 0.55]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours pessary Favours control
 
 
Analysis 1.2.   Comparison 1: Any pessary versus control, waiting list or no active treatment,


















IV, Fixed, 95% CI
0.10 [-0.73 , 0.93]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours pessary Favours control
 
 
Analysis 1.3.   Comparison 1: Any pessary versus control, waiting list or no active treatment,


















IV, Fixed, 95% CI
0.10 [-0.49 , 0.69]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours pessary Favours control
 
 
Analysis 1.4.   Comparison 1: Any pessary versus control, waiting list or no active treatment,
Outcome 4: Cure or improvement of bladder problems at 12 months (measured with bladder


















IV, Fixed, 95% CI
-0.15 [-0.55 , 0.25]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours pessary Favours control
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Analysis 1.5.   Comparison 1: Any pessary versus control, waiting list or no active treatment,
Outcome 5: Cure or improvement of bowel problems at 12 months (measured with bowel


















IV, Fixed, 95% CI
0.00 [-0.60 , 0.60]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours pessary Favours control
 
 
Analysis 1.6.   Comparison 1: Any pessary versus control, waiting list or no active treatment,
Outcome 6: Cure or improvement of sexual problems at 12 months (measured with sex


















IV, Fixed, 95% CI
-0.29 [-1.67 , 1.09]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours pessary Favours control
 
 
Comparison 2.   Any pessary versus PFMT







2.1 Women's perceived improvement of prolapse symptoms at
12 months (measured with PFDI-20; range: 0-300, higher score =
worse symptoms)




2.2 Women's perceived improvement of prolapse symptoms at
24 months (measured with PFDI-20; range: 0-300, higher score =
worse symptoms)




2.3 Women's perceived improvement of prolapse symptoms at
12 months (measured with POPDI-6; range: 0-100, higher score =
worse symptoms)




2.4 Women's perceived improvement of prolapse symptoms at
24 months (POPDI-6; range: 0-100, higher score = worse symp-
toms)




2.5 Women's perceived improvement of prolapse symptoms at
24 months




2.6 Prolapse-specific quality of life at 12 months (measured with
PFIQ-7, range: 0-300, higher score = worse QoL)




2.7 Prolapse-specific quality of life at 24 months (measured with
PFIQ-7, range: 0-300, higher score = worse QoL)
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2.8 Quality of life at 12 months (measured with PCS-12, range:
0-100, higher score = better health status)




2.9 Quality of life at 24 months (measures with PCS-12, range:
0-100, higher score = better health status)




2.10 Quality of life at 12 months (measured with MCS-12, range:
0-100, higher score = better health status)




2.11 Quality of life at 24 months (measured with MCS-12, range:
0-100, higher score = better health status)




2.12 Cure or improvement of bladder problems at 12 months
(measured with UDI-6, range: 0-100, higher score = worse symp-
toms)




2.13 Cure or improvement of bladder problems at 24 month
(measured with UDI-6, range: 0-100, higher score = worse symp-
toms)




2.14 Cure or improvement of bowel problems at 12 months
(measured with CRADI-8, range: 0-100, higher score = worse
symptoms)




2.15 Cure or improvement of bowel problems at 24 months
(measured with CRADI-8, range: 0-100, higher score = worse
symptoms)




2.16 Cure or improvement of sexual problems at 12 months
(measured with PISQ-12, range: 0-48, higher score = better sexual
functioning)




2.17 Cure or improvement of sexual problems at 24 months
(measured with PISQ-12, range: 0-48, higher score = better sexual
functioning)











Analysis 2.1.   Comparison 2: Any pessary versus PFMT, Outcome 1: Women's perceived improvement of


















IV, Fixed, 95% CI
-9.60 [-22.53 , 3.33]
Mean Difference
IV, Fixed, 95% CI
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Analysis 2.2.   Comparison 2: Any pessary versus PFMT, Outcome 2: Women's perceived improvement of


















IV, Fixed, 95% CI
-12.10 [-25.33 , 1.13]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.3.   Comparison 2: Any pessary versus PFMT, Outcome 3: Women's perceived improvement of


















IV, Fixed, 95% CI
-3.60 [-8.73 , 1.53]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.4.   Comparison 2: Any pessary versus PFMT, Outcome 4: Women's perceived improvement


















IV, Fixed, 95% CI
-4.20 [-9.03 , 0.63]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.5.   Comparison 2: Any pessary versus PFMT, Outcome 5:














M-H, Fixed, 95% CI
1.01 [0.64 , 1.59]
Risk Ratio
M-H, Fixed, 95% CI
0.7 0.85 1 1.2 1.5
Favours PFMT Favours pessary
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Analysis 2.6.   Comparison 2: Any pessary versus PFMT, Outcome 6: Prolapse-specific


















IV, Fixed, 95% CI
3.30 [-8.70 , 15.30]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.7.   Comparison 2: Any pessary versus PFMT, Outcome 7: Prolapse-specific


















IV, Fixed, 95% CI
-3.00 [-12.72 , 6.72]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.8.   Comparison 2: Any pessary versus PFMT, Outcome 8: Quality of life at


















IV, Fixed, 95% CI
1.20 [-2.45 , 4.85]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.9.   Comparison 2: Any pessary versus PFMT, Outcome 9: Quality of life at


















IV, Fixed, 95% CI
2.30 [-1.01 , 5.61]
Mean Difference
IV, Fixed, 95% CI
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Analysis 2.10.   Comparison 2: Any pessary versus PFMT, Outcome 10: Quality of life at


















IV, Fixed, 95% CI
-1.90 [-5.58 , 1.78]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.11.   Comparison 2: Any pessary versus PFMT, Outcome 11: Quality of life at


















IV, Fixed, 95% CI
-1.70 [-4.67 , 1.27]
Mean Difference
IV, Fixed, 95% CI




Analysis 2.12.   Comparison 2: Any pessary versus PFMT, Outcome 12: Cure or improvement of


















IV, Fixed, 95% CI
-2.70 [-9.45 , 4.05]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
 
 
Analysis 2.13.   Comparison 2: Any pessary versus PFMT, Outcome 13: Cure or improvement of


















IV, Fixed, 95% CI
-2.20 [-8.33 , 3.93]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
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Analysis 2.14.   Comparison 2: Any pessary versus PFMT, Outcome 14: Cure or improvement of bowel


















IV, Fixed, 95% CI
-3.50 [-8.61 , 1.61]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
 
 
Analysis 2.15.   Comparison 2: Any pessary versus PFMT, Outcome 15: Cure or improvement of bowel


















IV, Fixed, 95% CI
-4.50 [-9.38 , 0.38]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
 
 
Analysis 2.16.   Comparison 2: Any pessary versus PFMT, Outcome 16: Cure or improvement of sexual


















IV, Fixed, 95% CI
-2.30 [-5.20 , 0.60]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
 
 
Analysis 2.17.   Comparison 2: Any pessary versus PFMT, Outcome 17: Cure or improvement of sexual


















IV, Fixed, 95% CI
-1.00 [-3.49 , 1.49]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours PFMT Favours pessary
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Test for overall effect: Z = 3.05 (P = 0.002)



















M-H, Fixed, 95% CI
75.25 [4.70 , 1205.45]
75.25 [4.70 , 1205.45]
Risk Ratio
M-H, Fixed, 95% CI




Comparison 3.   Any pessary plus PFMT versus PFMT alone





Statistical method Effect size
3.1 Perceived improvement of prolapse symp-
toms at 12 months
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
3.2 Cure or improvement of bladder problems -
SUI
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
3.3 Cure or improvement of bladder problems -
UUI
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
3.4 Cure or improvement of bladder problems -
voiding difficulty
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
3.5 Number of women with adverse events - ab-
normal vaginal bleeding
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.6 Number of women with adverse events - de
novo voiding difficulty
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
 
 
Analysis 3.1.   Comparison 3: Any pessary plus PFMT versus PFMT alone,














M-H, Fixed, 95% CI
2.15 [1.58 , 2.94]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PFMT Favours pessary plus PFMT
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Analysis 3.2.   Comparison 3: Any pessary plus PFMT versus PFMT














M-H, Fixed, 95% CI
1.08 [0.60 , 1.96]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours PFMT Favours pessary plus PFMT
 
 
Analysis 3.3.   Comparison 3: Any pessary plus PFMT versus PFMT














M-H, Fixed, 95% CI
0.70 [0.41 , 1.20]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PFMT Favours pessary plus PFMT
 
 
Analysis 3.4.   Comparison 3: Any pessary plus PFMT versus PFMT alone,














M-H, Fixed, 95% CI
1.76 [1.03 , 3.00]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours PFMT Favours pessary plus PFMT
 
 
Analysis 3.5.   Comparison 3: Any pessary plus PFMT versus PFMT alone,
Outcome 5: Number of women with adverse events - abnormal vaginal bleeding
Study or Subgroup
Cheung 2016












M-H, Fixed, 95% CI
2.18 [0.69 , 6.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours pessary plus PFMT Favours PFMT
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Analysis 3.6.   Comparison 3: Any pessary plus PFMT versus PFMT alone,
Outcome 6: Number of women with adverse events - de novo voiding di<iculty
Study or Subgroup
Cheung 2016












M-H, Fixed, 95% CI
1.32 [0.54 , 3.19]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours pessary plus PFMT Favours PFMT
 
 
A P P E N D I C E S
Appendix 1. Search of the Cochrane Incontinence Specialised Register






All searches were of the keywords field of EndNote 2018.
Appendix 2. Search methods and strategies for the extra specific searches conducted for some of the previous
versions of this review
Electronic databases
MEDLINE (January 1966 to Week 5 August 2005) was searched on 14 September 2005 and PREMEDLINE (15 September 2005) was searched

















This set of terms was combined with the first two parts of the Cochrane Highly Sensitive Search Strategy for randomised controlled trials
(Appendix 5b.2, Cochrane Handbook, version 4.2, March 2003) using the Boolean operator 'AND'.
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CINAHL (January 1982 to February Week 4 2003) was searched on 13 March 2003, on OVID, using the following search terms:

















18.((descen$ adj2 (uter$ or genit$ or pelv$)).tw.
19.procident$.tw.
20.(vagin$ adj2 (eversion$ or evert$)).tw.
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PEDro (the Physiotherapy Evidence Database) (url: www.pedro.fhs.usyd.edu.au) produced by the Centre for Evidence-Based
Physiotherapy (CEBP), University of Sydney, Australia was searched on 13 October 2003 using the search term "prolapse".
The UK National Research Register (Issue 3, 2003), Controlled Clinical Trials (April 2003) and ZETOC database of conference abstracts
(April 2003) were searched using the search terms cystocele, urethrocele, rectocele, vault prolapse, uterine prolapse, vaginal prolapse,
pelvic organ prolapse, pelvic floor.
The reference lists of relevant articles were searched for other possibly relevant trials.
We did not impose any language or other restrictions on any of the searches.
Appendix 3. Search methods for the brief economic commentary (BEC)
We performed searches for the brief economic commentary (BEC). We searched:
• The NHS Economic Evaluation Database (NHS EED) on the Centre for Reviews and Dissemination (CRD) website (covering from the
earliest record in NHS EED, dating from 1968, up to and including 31 December 2014 when their coverage ended). Date of search: 13
February 2020.
As NHS EED is no longer actively updated we performed additional searches of the following databases to identify eligible studies added
to these databases from 1 January 2015 onwards (date of search: 13 February 2020):
• MEDLINE on OvidSP (covering 1 January 1946 to January February 1 2020); and
• Embase (on OvidSP) (covering 1 January 1974 to 2020 Week 06).
The economic evaluation search filters applied to our MEDLINE and Embase search strategies were those formerly used by the CRD to
identify published reports of full economic evaluations for indexing on NHS EED. These economic evaluation search filters remain freely
available on the CRD Database web-pages (CRD 2015). The other search lines in the MEDLINE and Embase search strategies were adapted
from the electronic search strategies run for our Cochrane Incontinence Specialised Register along with additional terms for this population
developed specifically for this review. Similarly, our NHS EED search strategy was adapted from search strategies run for our Specialised
Register and based on textword and MeSH terms (capturing relevant P-I-C concepts) used to identify eligible studies of intervention eIects.
We followed the current economic methods guidance (Shemilt 2019).
Ovid MEDLINE(R) on OvidSP covering 1 January 1946 to January February 1 2020 was searched on 13 February 2020 using the following
search strategy:
1. Economics/
2. exp "costs and cost analysis"/
3. Economics, Dental/




8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
9. (expenditure$ not energy).ti,ab.
10. value for money.ti,ab.
11. budget$.ti,ab.
12. or/1-11
13. ((energy or oxygen) adj cost).ti,ab.
14. (metabolic adj cost).ti,ab.
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15. ((energy or oxygen) adj expenditure).ti,ab.
16. or/13-15





22. 17 not 21
23. exp animals/ not humans/











35. (pelvi$ adj3 dysfunct$).tw.
36. (pelvi$ adj3 (disorder$ or relax$)).tw.
37. (vagin$ adj3 defect$).tw.
38. (urogen[SW1] ital adj5 prolaps$).tw.
39. (cervi$ adj5 prolaps$).tw.
40. exp Pelvic Organ Prolapse/
41. Pelvic Floor/
42. Pelvic Floor Disorders/
43. (pelvi$ adj2 floor[SW2] ).tw.
44. perineomet$.tw.
45. (prolaps$ adj5 rect$).tw.
46. or/25-45
47. 24 and 46
Embase on OvidSP covering 1 January 1974 to 2020 Week 06 was searched on 13 February 2020 using the following search strategy:
1. Health Economics/
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2. exp Economic Evaluation/
3. exp Health Care Cost/
4. pharmacoeconomics/
5. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
6. (expenditure$ not energy).ti,ab.







14. 9 not 13
15. (metabolic adj cost).ti,ab.
16. ((energy or oxygen) adj cost).ti,ab.
17. ((energy or oxygen) adj expenditure).ti,ab.
18. 15 or 16 or 17
19. 14 not 18
20. animal/
21. exp animal experiment/
22. nonhuman/
23. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.
24. 20 or 21 or 22 or 23
25. exp human/
26. human experiment/
27. 25 or 26
28. 24 not (24 and 27)
29. 19 not 28
30. conference abstract.pt.
31. 29 not 30
32. Uterus Prolapse/
33. Rectocele/
34. Vagina Prolapse/ or Cystocele/ or enterocele/
35. prolapse/ or pelvic floor prolapse/ or exp pelvic organ prolapse/ or perineal descent/ or exp visceral prolapse/
36. (prolaps$ adj5 (pelvi$ or vagin$ or genit$ or uter$ or vault$ or apical or urethr$ or segment$ or wall$)).tw.
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44. (pelvi$ adj3 dysfunct$).tw.
45. (pelvi$ adj3 (disorder$ or relax$)).tw.
46. (vagin$ adj3 defect$).tw.
47. (urogenital adj5 prolaps$).tw.
48. (cervi$ adj5 prolaps$).tw.




53. 31 and 52
NHS EED on the Centre for Reviews and Dissemination (CRD) website (covering from the earliest record in NHS EED, dating from 1968, up
to and including 31 December 2014 when their coverage ended). Date of search: 13 February 2020. The search strategy used is given below.
 
Search Hits
1 (MeSH DESCRIPTOR Prolapse EXPLODE ALL TREES) IN NHSEED
2 (MeSH DESCRIPTOR Cystocele EXPLODE ALL TREES) IN NHSEED
3 (MeSH DESCRIPTOR Pelvic Organ Prolapse EXPLODE ALL TREES) IN NHSEED
4 (MeSH DESCRIPTOR Rectal Prolapse EXPLODE ALL TREES) IN NHSEED
5 (MeSH DESCRIPTOR Uterine Prolapse EXPLODE ALL TREES) IN NHSEED
6 (MeSH DESCRIPTOR Visceral Prolapse EXPLODE ALL TREES) IN NHSEED
7 (MeSH DESCRIPTOR Rectocele EXPLODE ALL TREES) IN NHSEED
8 (MeSH DESCRIPTOR Pelvic Floor EXPLODE ALL TREES) IN NHSEED
9 (MeSH DESCRIPTOR Pelvic Floor Disorders EXPLODE ALL TREES) IN NHSEED
10 ((pelvi* ADJ5 prolaps*)) OR ((prolaps* ADJ5 pelvi*)) IN NHSEED
11 ((vagin* ADJ5 prolaps*)) OR ((prolaps* ADJ5 vagin*)) IN NHSEED
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12 ((genit* ADJ5 prolaps*)) OR ((prolaps* ADJ5 genit*)) IN NHSEED
13 ((uter* ADJ5 prolaps*)) OR ((prolaps* ADJ5 uter*)) IN NHSEED
14 ((vault* ADJ5 prolaps*)) OR ((prolaps* ADJ5 vault*)) IN NHSEED
15 ((apical ADJ5 prolaps*)) OR ((prolaps* ADJ5 apical)) IN NHSEED
16 ((urethr* ADJ5 prolaps*)) OR ((prolaps* ADJ5 urethr*)) IN NHSEED
17 ((segment* ADJ5 prolaps*)) OR ((prolaps* ADJ5 segment*)) IN NHSEED
18 ((wall* ADJ5 prolaps*)) OR ((prolaps* ADJ5 wall*)) IN NHSEED
19 ((rect* ADJ5 prolaps*)) OR ((prolaps* ADJ5 rect*)) IN NHSEED
20 ((urogen* ADJ5 prolaps*)) OR ((prolaps* ADJ5 urogen*)) IN NHSEED
21 ((cervi* ADJ5 prolaps*)) OR ((prolaps* ADJ5 cervi*)) IN NHSEED
22 ((pelvi* ADJ5 dysfunct*)) OR ((dysfunct* ADJ5 pelvi*)) IN NHSEED
23 ((pelvi* ADJ5 disorder*)) OR ((disorder* ADJ5 pelvi*)) IN NHSEED
24 ((pelvi* ADJ5 relax*)) OR ((relax* ADJ5 pelvi*)) IN NHSEED
25 ((pelvi* ADJ5 floor*)) OR ((floor* ADJ5 pelvi*)) IN NHSEED
26 ((vagin* ADJ5 defect*)) OR ((defect* ADJ5 vagin*)) IN NHSEED
27 (perineomet*) IN NHSEED
28 (cystocele*) OR (cystocoele*) IN NHSEED
29 (rectocele*) OR (rectocoele*) IN NHSEED
30 (urethrocele*) OR (urethrocoele*) IN NHSEED
31 (enterocele*) OR (enterocoele*) IN NHSEED
32 (proctocele*) OR (proctocoele*) IN NHSEED
33 (sigmoidocele*) OR (sigmoidocoele*) IN NHSEED
34 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28
OR #29 OR #30 OR #31 OR #32 OR #33
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
3 November 2020 New search has been performed The following changes were made for this update, published in
2020.
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Date Event Description
1. We updated the search to January 2020 and included a total
of four trials (Baessler 2019; Cheung 2016; Coolen 2018; Panman
2016). The crossover study included in the previous version of
the review has been excluded due to concerns about carry-over
data with this study design.
2. We amended the outcomes to reflect those that are most im-
portant to women and to clinical decision-makers. We presented
separate outcomes for resolution of prolapse symptoms and im-
provement in prolapse and we also included as an outcome the
number of women with adverse events.
3. We removed two comparisons due to their lack of contribu-
tion to the evidence base regarding the effectiveness of pessaries
as a treatment: pessary plus another treatment versus pessary
alone; and differing frequencies of pessary device review or de-
vice change.
4. We conducted and included a brief economic commentary to
summarise the principal findings of full economic evaluations
that compared pessaries with alternative treatment interven-
tions for pelvic organ prolapse in women.
5. We substantially modified the methodology of the review in
accordance with current Cochrane guidance, including adding
'Summary of findings' tables and assessing the certainty of the
body of evidence using the GRADE approach.
6. The authorship of the review has changed.
3 November 2020 New citation required and conclusions
have changed
1. This version of the review includes four RCTs, leading to the
following conclusions: We are uncertain if pessaries improve
pelvic organ prolapse symptoms for women compared with no
treatment or PFMT but pessaries in addition to PFMT probably
improve women's pelvic organ prolapse symptoms and pro-
lapse-specific quality of life. However, there may be an increased
risk of adverse events with pessaries compared to PFMT.
 
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 2, 2004
 
Date Event Description
7 August 2008 Amended Converted to new review format.
26 January 2006 New search has been performed Minor update: 26/01/06 New studies sought but none found:
26/10/05
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
For this update, published in 2020, we made the following changes.
1. We updated the search to January 2020 and included a total of four trials (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016). The
crossover study included in the previous version of the review (Bugge 2013b) has been excluded due to concerns about carry-over data
with this study design.
2. We amended the outcomes to reflect those that are most important to women and to clinical decision-makers. We presented separate
outcomes for resolution of prolapse symptoms and improvement in prolapse and we also included as an outcome the number of women
with adverse events.
3. We removed two comparisons due to their lack of contribution to the evidence base regarding the eIectiveness of pessaries as a
treatment: pessary plus another treatment versus pessary alone; and diIering frequencies of pessary device review or device change.
4. We conducted and included a brief economic commentary to summarise the principal findings of full economic evaluations that
compared pessaries with alternative treatment interventions for pelvic organ prolapse in women.
5. We substantially modified the methodology of the review in accordance with current Cochrane guidance, including adding 'Summary
of findings' tables and assessing the certainty of the body of evidence using the GRADE approach.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Pelvic Organ Prolapse  [*therapy];  *Pessaries;  Randomized Controlled Trials as Topic;  Rectal Prolapse  [*therapy];  Urethral Diseases
 [therapy];  Urinary Bladder Diseases  [therapy];  Uterine Prolapse  [therapy]
MeSH check words
Female; Humans
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